NO308025B1 - FremgangsmÕte til Õ kontrollere et iontoforetisk medikamenttilførsel-apparat, og apparater for innføring av hhv. et ionisert terapeutisk agens og et ikke-ladet terapeutisk agens i et legeme - Google Patents

FremgangsmÕte til Õ kontrollere et iontoforetisk medikamenttilførsel-apparat, og apparater for innføring av hhv. et ionisert terapeutisk agens og et ikke-ladet terapeutisk agens i et legeme Download PDF

Info

Publication number: NO308025B1
Authority: NO; Norway
Prior art keywords: level; current; therapeutic agent; iontophoretic; electrodes
Prior art date: 1990-03-30

Application number

NO923769A

Other languages

English (en)

Norwegian (no)

Other versions

NO923769L (no

NO923769D0 (no

Inventor

Paul D Sorenson

John D Bradzinski

Gary A Lattin

Larry A Mcnichols

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1992-09-28

Publication date

2000-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27054046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308025(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-09-28 Application filed by Alza Corp filed Critical Alza Corp

1992-09-28 Publication of NO923769D0 publication Critical patent/NO923769D0/no

1992-11-30 Publication of NO923769L publication Critical patent/NO923769L/no

2000-07-10 Publication of NO308025B1 publication Critical patent/NO308025B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 45
229940124597 therapeutic agent Drugs 0.000 title claims abstract description 24
238000012377 drug delivery Methods 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title claims description 10
230000001225 therapeutic effect Effects 0.000 claims abstract description 12
239000003795 chemical substances by application Substances 0.000 claims abstract description 10
239000007788 liquid Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
238000012423 maintenance Methods 0.000 abstract description 3
229940079593 drug Drugs 0.000 description 21
210000001519 tissue Anatomy 0.000 description 11
239000000126 substance Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000812 cholinergic antagonist Substances 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
238000005370 electroosmosis Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102400000739 Corticotropin Human genes 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
108010004977 Vasopressins Proteins 0.000 description 2
102000002852 Vasopressins Human genes 0.000 description 2
229940125681 anticonvulsant agent Drugs 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
238000004980 dosimetry Methods 0.000 description 2
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000003667 hormone antagonist Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
102100025841 Cholecystokinin Human genes 0.000 description 1
101800001982 Cholecystokinin Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102400000932 Gonadoliberin-1 Human genes 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
108010057021 Menotropins Proteins 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102400000827 Saposin-D Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
108010078233 Thymalfasin Proteins 0.000 description 1
102400000800 Thymosin alpha-1 Human genes 0.000 description 1
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108010047196 Urofollitropin Proteins 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
229940116211 Vasopressin antagonist Drugs 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
108010060162 alglucerase Proteins 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940124346 antiarthritic agent Drugs 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
229940005486 antimigraine preparations Drugs 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000003152 bradykinin antagonist Substances 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229940107137 cholecystokinin Drugs 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
229960002976 chymopapain Drugs 0.000 description 1
238000010276 construction Methods 0.000 description 1
150000001885 cortisol derivatives Chemical class 0.000 description 1
229940037530 cough and cold preparations Drugs 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
229960002845 desmopressin acetate Drugs 0.000 description 1
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
-1 diagnostics Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
229940091249 fluoride supplement Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000003325 follicular Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229960001442 gonadorelin Drugs 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
230000002445 parasympatholytic effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229950011188 pentigetide Drugs 0.000 description 1
KQDIGHIVUUADBZ-PEDHHIEDSA-N pentigetide Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KQDIGHIVUUADBZ-PEDHHIEDSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002089 prostaglandin antagonist Substances 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
238000004080 punching Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
229960004231 thymalfasin Drugs 0.000 description 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960004371 urofollitropin Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000003038 vasopressin antagonist Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Radiology & Medical Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Electrotherapy Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
External Artificial Organs (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Compositions Of Macromolecular Compounds (AREA)

NO923769A 1990-03-30 1992-09-28 FremgangsmÕte til Õ kontrollere et iontoforetisk medikamenttilførsel-apparat, og apparater for innføring av hhv. et ionisert terapeutisk agens og et ikke-ladet terapeutisk agens i et legeme NO308025B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50217690A	1990-03-30	1990-03-30
US07/671,306 US5207752A (en)	1990-03-30	1991-03-21	Iontophoretic drug delivery system with two-stage delivery profile
PCT/US1991/001941 WO1991015258A1 (en)	1990-03-30	1991-03-22	Iontophoretic drug delivery system with two-stage delivery profile

Publications (3)

Publication Number	Publication Date
NO923769D0 NO923769D0 (no)	1992-09-28
NO923769L NO923769L (no)	1992-11-30
NO308025B1 true NO308025B1 (no)	2000-07-10

Family

ID=27054046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923769A NO308025B1 (no)	1990-03-30	1992-09-28	FremgangsmÕte til Õ kontrollere et iontoforetisk medikamenttilførsel-apparat, og apparater for innføring av hhv. et ionisert terapeutisk agens og et ikke-ladet terapeutisk agens i et legeme

Country Status (14)

Country	Link
US (1)	US5207752A (da)
EP (1)	EP0522092B1 (da)
JP (1)	JP3181289B2 (da)
KR (1)	KR0169084B1 (da)
AT (1)	ATE114118T1 (da)
AU (1)	AU638581B2 (da)
CA (1)	CA2079316C (da)
DE (1)	DE69105202T2 (da)
DK (1)	DK0522092T3 (da)
ES (1)	ES2067939T3 (da)
FI (1)	FI110066B (da)
GR (1)	GR3015116T3 (da)
NO (1)	NO308025B1 (da)
WO (1)	WO1991015258A1 (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5207752A (en)	1990-03-30	1993-05-04	Alza Corporation	Iontophoretic drug delivery system with two-stage delivery profile
MX9206990A (es)	1991-12-03	1993-06-01	Alza Corp	Dispositivo iontoforetico de surtido y suministro de energia para el mismo.
US5505715A (en) *	1994-02-25	1996-04-09	Bristol-Myers Squibb Company	Iontophoretic transdermal delivery of deoxyspergualin compounds
US7027859B1 (en)	1994-09-26	2006-04-11	Alza Corporation	Electrotransport delivery device having improved safety and reduced abuse potential
US5697896A (en) *	1994-12-08	1997-12-16	Alza Corporation	Electrotransport delivery device
US5700481A (en) *	1995-03-17	1997-12-23	Takeda Chemical Industries, Ltd.	Transdermal drug delivery process
US6032073A (en) *	1995-04-07	2000-02-29	Novartis Ag	Iontophoretic transdermal system for the administration of at least two substances
IE960312A1 (en) *	1995-06-02	1996-12-11	Alza Corp	An electrotransport delivery device with voltage boosting¹circuit
US5983130A (en) *	1995-06-07	1999-11-09	Alza Corporation	Electrotransport agent delivery method and apparatus
AU710793B2 (en) *	1995-06-07	1999-09-30	Alza Corporation	Electrotransport agent delivery method and apparatus
WO1997014473A1 (en) *	1995-10-18	1997-04-24	Novartis Ag	Thermopile powered transdermal drug delivery device
US6718201B1 (en) *	1996-06-07	2004-04-06	Alza Corporation	Electrotransport agent delivery method and apparatus
AU3404197A (en) *	1996-06-19	1998-01-07	Becton Dickinson & Company	Iontophoretic delivery of cell adhesion inhibitors
US5857994A (en) *	1996-10-01	1999-01-12	Becton, Dickinson And Company	Awakenable iontophoretic/delivery device for reducing electrical sensation upon application thereof
FR2766093B1 (fr) *	1997-07-15	1999-09-03	Lhd Lab Hygiene Dietetique	Procede de commande d'un dispositif d'administration transdermique de medicament sous champ electrique
WO1999030773A1 (en)	1997-12-16	1999-06-24	Alza Corporation	Regulator with artificial load to maintain regulated delivery
JP4362012B2 (ja)	1997-12-17	2009-11-11	アルザ・コーポレーション	電流がプログラム調整されたイオン導入法
ATE197408T1 (de)	1998-01-30	2000-11-11	Novo Nordisk As	Eine injektionsspritze
BR0008123A (pt)	1999-02-10	2001-11-13	Gmp Drug Delivery Inc	Dispositivo baseado em emplastro para aumentar aliberação local de um agente de tratamento paradentro de tecidos alvo, e, processo de liberaçãode um agente de tratamento para dentro detecidos alvo de uma vesìcula corporal
US6471675B1 (en)	1999-04-30	2002-10-29	Medtronic, Inc.	Passive flow control devices for implantable pumps
TW453884B (en)	1999-09-16	2001-09-11	Novo Nordisk As	Dose setting limiter
US6663602B2 (en)	2000-06-16	2003-12-16	Novo Nordisk A/S	Injection device
IL155730A0 (en) *	2000-11-03	2003-11-23	Biomedicines Inc	Method for short-term and long-term drug dosimetry
CA2466228A1 (en) *	2001-11-09	2003-08-07	Biomedicines, Inc.	Method for treating diseases with omega interferon
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0304822D0 (en) *	2003-03-03	2003-04-09	Dca Internat Ltd	Improvements in and relating to a pen-type injector
US9205197B2 (en) *	2003-03-03	2015-12-08	Sanofi-Aventis Deutschland Gmbh	Drug delivery device dose setting mechanism
GB0308267D0 (en) *	2003-04-10	2003-05-14	Dca Design Int Ltd	Improvements in and relating to a pen-type injector
US7220778B2 (en) *	2003-04-15	2007-05-22	The General Hospital Corporation	Methods and devices for epithelial protection during photodynamic therapy
US7596407B2 (en) *	2004-03-26	2009-09-29	Solvay Pharmaceuticals, B.V.	Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
EP1595542A1 (en) *	2004-03-26	2005-11-16	Solvay Pharmaceuticals B.V.	Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
EP1804865B1 (en)	2004-10-21	2009-09-30	Novo Nordisk A/S	Dial-down mechanism for wind-up pen
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
EP1855744A1 (en) *	2005-02-28	2007-11-21	Novo Nordisk A/S	A dose setting mechanism for an injection device
US7856263B2 (en)	2005-04-22	2010-12-21	Travanti Pharma Inc.	Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
US20090043264A1 (en) *	2005-04-24	2009-02-12	Novo Nordisk A/S	Injection Device
BRPI0616487A2 (pt) *	2005-09-30	2011-06-21	Tti Ellebeau Inc	aparato e método de iontoforese para liberação sistêmica de agentes ativos
WO2007046103A2 (en) *	2005-10-19	2007-04-26	Perf-Action Technologies Ltd.	System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof
US8361036B2 (en)	2006-03-10	2013-01-29	Novo Nordisk A/S	Injection device having a gearing arrangement
WO2007104636A1 (en)	2006-03-10	2007-09-20	Novo Nordisk A/S	An injection device and a method of changing a cartridge in the device
EA023147B1 (ru) *	2006-04-13	2016-04-29	Тева Фармасьютикалс Интернешнл Гмбх	Трансдермальный пластырь для лечения мигрени
AU2012261753B2 (en) *	2006-04-13	2015-03-05	Teva Pharmaceuticals International Gmbh	Transdermal methods and systems for the delivery of anti-migraine compounds
ATE458517T1 (de)	2006-05-16	2010-03-15	Novo Nordisk As	Getriebemechanismus für ein injektionsgerät
WO2007132526A1 (ja) *	2006-05-16	2007-11-22	Rorze Corporation	シャトル型搬送装置、マイクロプレート供給回収装置、マイクロプレート用ピックアップ装置、マイクロプレート用カセット、及びマイクロプレート用収納棚
BRPI0712028A2 (pt)	2006-05-18	2011-12-20	Novo Nordisk As	dispositivo de injenção com um meio de travamento de modo
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotic delivery systems and piston assemblies
US8728059B2 (en) *	2006-09-29	2014-05-20	Covidien Lp	System and method for assuring validity of monitoring parameter in combination with a therapeutic device
WO2008095762A1 (en)	2007-02-05	2008-08-14	Novo Nordisk A/S	Injection button
RU2468829C2 (ru)	2007-03-23	2012-12-10	Ново Нордиск А/С	Инъекционное устройство, содержащее стопорную гайку
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US8197844B2 (en)	2007-06-08	2012-06-12	Activatek, Inc.	Active electrode for transdermal medicament administration
ES2454974T3 (es) *	2007-06-27	2014-04-14	The General Hospital Corporation	Aparato para la inhibición óptica de la terapia fotodinámica
US20090043244A1 (en) *	2007-08-08	2009-02-12	Inan Omer T	Electrotransport Drug Delivery Device Adaptable to Skin Resistance Change
US8862223B2 (en)	2008-01-18	2014-10-14	Activatek, Inc.	Active transdermal medicament patch and circuit board for same
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
US20090259176A1 (en) *	2008-04-09	2009-10-15	Los Gatos Research, Inc.	Transdermal patch system
US20090312689A1 (en) *	2008-06-05	2009-12-17	Alza Corporation	Adjustable Current Electrotransport Fentanyl Delivery Device
US8366600B2 (en) *	2008-06-19	2013-02-05	Nupathe Inc.	Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) *	2008-06-19	2012-04-10	Nupathe, Inc.	Pharmacokinetics of iontophoretic sumatriptan administration
WO2010078313A1 (en) *	2008-12-30	2010-07-08	Nupathe, Inc.	Electronic control of drug delivery system
US9008765B2 (en)	2009-02-12	2015-04-14	Incube Labs, Llc	System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
US8961492B2 (en)	2009-02-12	2015-02-24	Incube Labs, Llc	System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US8190252B2 (en)	2009-02-12	2012-05-29	Incube Labs, Llc	Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US8903485B2 (en)	2009-08-06	2014-12-02	Incube Labs, Llc	Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
CN105796533A (zh) *	2009-08-10	2016-07-27	泰华制药国际有限公司	用离子电渗疗法治疗恶心和偏头痛的方法
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20110087153A1 (en) *	2009-10-13	2011-04-14	Angelov Angel S	Transdermal Methods And Systems For The Delivery Of Rizatriptan
US8685038B2 (en)	2009-12-07	2014-04-01	Incube Labs, Llc	Iontophoretic apparatus and method for marking of the skin
WO2011100376A2 (en)	2010-02-10	2011-08-18	Incube Labs, Llc	Methods and architecture for power optimization of iontophoretic transdermal drug delivery
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3626304A1 (en)	2011-03-24	2020-03-25	Incube Labs, Llc	System and method for biphasic transdermal iontophoretic delivery of therapeutic agents
US8428708B1 (en) *	2012-05-21	2013-04-23	Incline Therapeutics, Inc.	Self-test for analgesic product
US8428709B1 (en)	2012-06-11	2013-04-23	Incline Therapeutics, Inc.	Current control for electrotransport drug delivery
CA2861706A1 (en)	2011-12-29	2013-07-04	Novo Nordisk A/S	Dial-up/dial-down mechanism for wind-up pen
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
USD933219S1 (en)	2018-07-13	2021-10-12	Intarcia Therapeutics, Inc.	Implant removal tool and assembly
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3163166A (en) *	1961-04-28	1964-12-29	Colgate Palmolive Co	Iontophoresis apparatus
US3618601A (en) *	1969-10-16	1971-11-09	Thatcher W Richardson	Iontophoresis unit
US3677268A (en) *	1969-11-28	1972-07-18	Sherwood Medical Ind Inc	Iontophoresis electrode
US3794910A (en) *	1971-07-26	1974-02-26	Sherwood Medical Ind Inc	Iontophoresis and conductivity analysis circuit
DE2339648C3 (de) *	1973-08-04	1979-09-13	Trebbin, Peter, 8833 Eichstaett	Anästhesiegerät zur Behandlung der Zähne
US4141359A (en) *	1976-08-16	1979-02-27	University Of Utah	Epidermal iontophoresis device
US4211222A (en) *	1976-08-25	1980-07-08	Robert Tapper	Iontophoretic burn-protection method
JPS5347192A (en) *	1976-10-13	1978-04-27	Matsushita Electric Industrial Co Ltd	Device for introducing fluorine ion to tooth
US4325367A (en) *	1977-06-13	1982-04-20	Robert Tapper	Iontophoretic treatment apparatus
US4177817A (en) *	1978-02-01	1979-12-11	C. R. Bard, Inc.	Dual terminal transcutaneous electrode
US4215696A (en) *	1978-03-20	1980-08-05	Graphic Controls Corporation	Biomedical electrode with pressurized skin contact
US4209020A (en) *	1978-09-19	1980-06-24	Nielsen R Frederick	Electrode assembly
US4340047A (en) *	1978-10-18	1982-07-20	Robert Tapper	Iontophoretic treatment apparatus
US4301794A (en) *	1978-10-18	1981-11-24	Robert Tapper	Method for iontophoretic treatment
US4292968A (en) *	1979-11-26	1981-10-06	Sybron Corporation	Electric supply for ion therapy
AU546785B2 (en) *	1980-07-23	1985-09-19	Commonwealth Of Australia, The	Open-loop controlled infusion of diabetics
JPS5810066A (ja) *	1981-07-10	1983-01-20	株式会社アドバンス	イオントフオレ−ゼ用プラスタ−構造体
US4450844A (en) *	1981-11-23	1984-05-29	Hill Top Research, Inc.	Patch system for use on the skin
EP0140980A4 (en) *	1983-04-15	1987-09-15	Jack Kenneth Ibbott	APPARATUS USING A FLAT BATTERY.
US4622031A (en) *	1983-08-18	1986-11-11	Drug Delivery Systems Inc.	Indicator for electrophoretic transcutaneous drug delivery device
US4731926A (en) *	1985-02-19	1988-03-22	Drug Delivery Systems Inc.	Method of manufacturing disposable and/or replenishable transdermal drug applicators
US4557723A (en) *	1983-08-18	1985-12-10	Drug Delivery Systems Inc.	Applicator for the non-invasive transcutaneous delivery of medicament
US4640689A (en) *	1983-08-18	1987-02-03	Drug Delivery Systems Inc.	Transdermal drug applicator and electrodes therefor
US4708716A (en) *	1983-08-18	1987-11-24	Drug Delivery Systems Inc.	Transdermal drug applicator
US4808152A (en) *	1983-08-18	1989-02-28	Drug Delivery Systems Inc.	System and method for controlling rate of electrokinetic delivery of a drug
US4883457A (en) *	1983-08-18	1989-11-28	Drug Delivery Systems Inc.	Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US4851229A (en) *	1983-12-01	1989-07-25	Alza Corporation	Composition comprising a therapeutic agent and a modulating agent
ATE50915T1 (de) *	1985-06-10	1990-03-15	Drug Delivery Systems Inc	Anlage und verfahren zur steuerung der elektrokinetischen lieferungsgeschwindigkeit einer arznei.
US4698062A (en) *	1985-10-30	1987-10-06	Alza Corporation	Medical device for pulsatile transdermal delivery of biologically active agents
US4725263A (en) *	1986-07-31	1988-02-16	Medtronic, Inc.	Programmable constant current source transdermal drug delivery system
US4822334A (en) *	1986-12-04	1989-04-18	Robert Tapper	Electrical dosimetry control system
US4731049A (en) *	1987-01-30	1988-03-15	Ionics, Incorporated	Cell for electrically controlled transdermal drug delivery
EP0313638A4 (en) *	1987-05-15	1989-06-14	Martin H Newman	IONTOPHORESIS INOPHORESIS DRUG ADMINISTRATION SYSTEM.
US4865582A (en) *	1987-06-05	1989-09-12	Drug Delivery Systems Inc.	Disposable transdermal drug applicators
US5207752A (en)	1990-03-30	1993-05-04	Alza Corporation	Iontophoretic drug delivery system with two-stage delivery profile

1991
- 1991-03-21 US US07/671,306 patent/US5207752A/en not_active Expired - Lifetime
- 1991-03-22 DE DE69105202T patent/DE69105202T2/de not_active Expired - Fee Related
- 1991-03-22 DK DK91911198.9T patent/DK0522092T3/da active
- 1991-03-22 ES ES91911198T patent/ES2067939T3/es not_active Expired - Lifetime
- 1991-03-22 CA CA002079316A patent/CA2079316C/en not_active Expired - Lifetime
- 1991-03-22 AU AU79915/91A patent/AU638581B2/en not_active Expired
- 1991-03-22 WO PCT/US1991/001941 patent/WO1991015258A1/en not_active Ceased
- 1991-03-22 AT AT91911198T patent/ATE114118T1/de not_active IP Right Cessation
- 1991-03-22 KR KR1019920702381A patent/KR0169084B1/ko not_active Expired - Fee Related
- 1991-03-22 JP JP51059091A patent/JP3181289B2/ja not_active Expired - Lifetime
- 1991-03-22 EP EP91911198A patent/EP0522092B1/en not_active Revoked
1992
- 1992-09-28 NO NO923769A patent/NO308025B1/no not_active IP Right Cessation
- 1992-09-28 FI FI924352A patent/FI110066B/fi active
1995
- 1995-02-20 GR GR950400340T patent/GR3015116T3/el unknown

Also Published As

Publication number	Publication date
DE69105202T2 (de)	1995-03-23
NO923769L (no)	1992-11-30
ES2067939T3 (es)	1995-04-01
GR3015116T3 (en)	1995-05-31
JPH05505964A (ja)	1993-09-02
EP0522092A1 (en)	1993-01-13
JP3181289B2 (ja)	2001-07-03
DE69105202D1 (de)	1994-12-22
KR930700181A (ko)	1993-03-13
KR0169084B1 (ko)	1999-01-15
DK0522092T3 (da)	1995-03-13
AU638581B2 (en)	1993-07-01
NO923769D0 (no)	1992-09-28
FI924352L (fi)	1992-09-28
FI110066B (fi)	2002-11-29
WO1991015258A1 (en)	1991-10-17
AU7991591A (en)	1991-10-30
EP0522092B1 (en)	1994-11-17
FI924352A0 (fi)	1992-09-28
CA2079316C (en)	2002-01-01
ATE114118T1 (de)	1994-12-15
CA2079316A1 (en)	1991-10-01
US5207752A (en)	1993-05-04

Legal Events

Date	Code	Title	Description
2011-04-18	MK1K	Patent expired

Publication	Publication Date	Title
NO308025B1 (no)	2000-07-10	FremgangsmÕte til Õ kontrollere et iontoforetisk medikamenttilførsel-apparat, og apparater for innføring av hhv. et ionisert terapeutisk agens og et ikke-ladet terapeutisk agens i et legeme
JP3779240B2 (ja)	2006-05-24	イオン導入有効剤投与系の駆動に必要な電力源の有功電気容量を減ずる方法
KR100482229B1 (ko)	2005-06-16	전기운반작용제전달방법및장치
US5697896A (en)	1997-12-16	Electrotransport delivery device
US5221254A (en)	1993-06-22	Method for reducing sensation in iontophoretic drug delivery
US20030018296A1 (en)	2003-01-23	Electrotransport delivery device with voltage boosting circuit
JP2009219892A (ja)	2009-10-01	電流がプログラム調整されたイオン導入法
US7136698B2 (en)	2006-11-14	Electrotransport agent delivery apparatus
AU710793B2 (en)	1999-09-30	Electrotransport agent delivery method and apparatus